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Introduction: Sexually transmitted infections are a public health problem worldwide. Their 
inadequate antimicrobial management has been associated with a higher risk of recurrence. 
Objective: To characterize the main sexually transmitted infections, the adherence to 
clinical practice guidelines, and the factors associated with recurrence in Colombia.
Materials and methods: We conducted an observational study to identify the main 
sexually transmitted infections, the sociodemographic variables, and the pharmacological 
management in a patient cohort from a population database of 6.5 million people affiliated 
with the Colombian health system. We made a multivariate analysis to identify the variables 
associated with recurrence.
Results: We detected 3,158 patients with a mean age of 41.8 ± 14.5 years, of whom 63.1% 
were men. We found 4.030 episodes of sexually transmitted infections, predominantly urethral 
syndrome (27.5%). Only 13.6% of patients with urethral syndrome, ulcerative syndrome, or 
genital warts were managed in compliance with clinical practice guidelines and 20.6% were 
dispensed condoms; 16.7% of patients had recurrences and being male (OR=1.32; 95%CI 
1.08-1.63), <30 years old (OR=1.72; 95%CI 1.40-2.13), being treated in municipalities other 
than capital cities (OR=1.43; 95%CI 1.06-1.94), and having received inadequate treatment for 
the first episode (OR=1.93; 95%CI 1.52-2.39) were associated with recurrence.
Conclusions: The majority of patients with sexually transmitted infections were not treated 
in compliance with clinical practice guidelines and those who did not have adequate 
management had a higher risk of recurrence.
Keywords: Sexually transmitted diseases; urethritis; recurrence; male; condoms; public health.
Caracterización de las infecciones de transmisión sexual, su tratamiento 
farmacológico y la recurrencia en una población colombiana
Introducción. Las infecciones de transmisión sexual constituyen actualmente un problema 
de salud pública en el mundo. Su inadecuado tratamiento antimicrobiano se ha relacionado 
con un mayor riesgo de recurrencias. 
Objetivo. Caracterizar las principales infecciones de transmisión sexual, el cumplimiento 
de las guías de práctica clínica de Colombia y los factores asociados con las recurrencias.
Materiales y métodos. Se hizo un estudio observacional para determinar las principales 
infecciones de transmisión sexual, las variables sociodemográficas y el tratamiento 
farmacológico en una cohorte de pacientes registrados en una base de datos poblacional 
de 6,5 millones de personas afiliadas al Sistema de Salud de Colombia. Se hizo un análisis 
multivariado para establecer las variables asociadas con las recurrencias. 
Resultados. Se detectaron 3.158 pacientes; su edad media era de 41,8 ±14,5 años y 
63,1 % de ellos correspondía a hombres; se encontraron 4.030 episodios de infecciones de 
transmisión sexual con predominio del síndrome uretral (27,5 %). El 13,6 % de los pacientes 
con síndrome uretral, ulceroso o con verrugas genitales se manejó según las guías de 
práctica clínica. El 20,6 % tenía acceso a condones y el 16,7 % presentó recurrencias. Ser 
hombre (OR=1,32; IC95% 1,08-1,63), tener <30 años (OR=1,72; IC95% 1,40-2,13), ser tratado 
en municipios distintos a ciudades capitales (OR=1,43; IC95% 1,06-1,94) y haber recibido un 
tratamiento inadecuado en el primer episodio (OR=1,93; IC95% 1,52-2,39) fueron factores 
asociados con las recurrencias.
Conclusiones. La mayoría de los pacientes con infecciones de transmisión sexual no 
fueron tratados según las guías de práctica clínica y quienes no tuvieron un manejo 
adecuado presentaban mayor riesgo de recurrencias.
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Sexually transmitted diseases are a variety of clinical syndromes and 
infections caused by pathogens transmitted during sexual intercourse (1). In 
recent years, many experts have suggested calling them sexually transmitted 
infections instead because the concept of disease involves a medical problem, 
usually with clear signs and symptoms, while sexually transmitted diseases 
also affect asymptomatic patients and, therefore, not all infections can be 
considered diseases (2,3).
Sexually transmitted infections are among the most common contagious 
conditions affecting individuals’ health and lives around the world (4,5) and 
they are currently considered a global public health problem (5). Sexually 
transmitted infections prevalence depends on socioeconomic conditions, 
cultural and moral beliefs, and diagnostic and therapeutic options (3). 
According to the World Health Organization (WHO), every day, more than 
a million people acquire a sexually transmitted infection, and it has been 
estimated that 376 million new sexually transmitted infections cases occurred 
in 2016, among them, trichomoniasis (156 million), chlamydia (127 million), 
gonorrhea (87 million), and syphilis (6.3 million). Besides, the number of 
people with genital herpes exceeds 500 million and approximately 240 million 
suffer from chronic hepatitis B (6). In 2016, the prevalence of chlamydia 
infection in Colombian men was 9.2% and 7.4% among women while syphilis 
prevalence was 1.2% overall while gonorrhea prevalence was 0.7% in women 
and 0.6% in men (7).
These infections can cause acute urogenital conditions such as urethritis, 
cervicitis, vaginitis, and ulceration in the genitals, among others, and 
some may involve the rectum and pharynx. Several etiological agents are 
associated with serious short- and long-term complications (4). Sexually 
transmitted infections can be caused by viruses, bacteria, and parasites; they 
include mainly eight infections, four of which can be cured, namely, syphilis, 
gonorrhea, chlamydia, and trichomoniasis while the other four are caused by 
viruses (hepatitis B, herpes simplex, HIV and human papillomavirus) and are 
incurable, although there are treatments to attenuate, control, or modify the 
symptoms or the disease (6,8).
The lack of treatment is also considered a public health problem because 
untreated infections can lead to harmful consequences for individuals’ health 
(9). In this sense, the Colombian Ministry of Health and Social Protection 
and the Administrative Department of Science, Technology, and Innovation 
(Colciencias) published in 2013 the clinical practice guidelines for the 
syndromic approach to the diagnosis and treatment of patients with sexually 
transmitted infections and other genital tract infections aimed at providing health 
professionals with evidence on therapy effectiveness and safety to reduce the 
variability found in clinical practice, among other objectives (10). However, 
few studies in the country have addressed this topic and the pharmacological 
management indicated for patients with sexually transmitted infections is 
unknown. Therefore, we sought to characterize the main sexually transmitted 
infections, the adherence of their treatment to clinical practice guidelines, and 
the factors associated with recurrence in a Colombian population.
Materials and methods
Study design
We conducted an observational, descriptive, and retrospective cohort study 
on the treatment schemes used in the management of some sexually transmitted 
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infections and their recurrence. Data were obtained from a population database 
of drugs dispensed that gathers information from about 6.5 million individuals 
affiliated with the contributory regime of the Colombian Health System through 
five insurers known in the country as health-promoting companies corresponding 
to approximately 30.0% of the actively affiliated population in this regime in the 
country and 14.3% of the Colombian total population.
We selected patients of either sex aged 14 or older treated in outpatient 
units from January 1 to December 31, 2015. We excluded those who had 
had a sexually transmitted infection in 2013 or 2014. We followed the patients 
until June 30, 2019. Besides, we analyzed the International Classification 
of Diseases, 10th revision (ICD-10) codes related to sexually transmitted 
infections and the drugs prescribed for their management.
The ICD-10 diagnostic codes used for patient identification were the following:
• Urethral discharge syndrome and/or cervicitis:
 » Urethritis: N341, N342, N370
 » Gonococcal infections: A540-A542, A546-A549
 » Chlamydial infections: A560-A563, A568
 » Trichomoniasis: A590, A598, A599
• Ulcerative syndrome: 
 » Syphilis: A510-A512, A539, N742
 » Genital herpes: A600, A601, A609
 » Soft chancre: A57X
 » Lymphogranuloma venereum: A55X
 » Granuloma inguinale: A58X
 » Anogenital warts: A630
• Others:
 » Hepatitis B: B160-B162, B169, B170, B180, B181
 » Hepatitis C: B171, B182
 » HIV: B200-B213, B217-B222, B227, B230-B232, B238, B24X, F024, 
R75X.
Based on the information on the use of drugs by the affiliated population, 
systematically recorded by the dispensing company Audifarma SA, we 
designed a database to collect the following groups of variables:
1. Sociodemographic: sex, age, city of dispensation.
2. Chronic comorbidities: we identified the main cardiovascular, endocrine, 
rheumatic, urological, kidney, psychiatric, neurological, digestive, 
respiratory, and neoplastic diseases from the reported ICD-10 
diagnostic codes.
3. Drugs used in the management of some sexually transmitted infections. 
Management was considered adequate when the prescribed antibiotic, 
dose, and duration of treatment followed the Colombian clinical practice 
guidelines (10), as follows:
 » Urethral discharge syndrome or cervicitis:
 » Urethritis: ceftriaxone (500 mg IM single dose) and azithromycin (1 g 
orally single dose)
 » Gonococcal infections: ceftriaxone (500 mg IM single dose) or 
spectinomycin (2 g IM single dose)
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 » Chlamydial infections: azithromycin (1 g orally single dose) or 
doxycycline (100 mg orally administered every 12 hours for 7 days)
 » Trichomoniasis: tinidazole (2 g oral single dose) or metronidazole (2 
g orally single dose)
 » Ulcerative syndrome:
 » Syphilis: benzathine penicillin G (2,400,000 IU single-dose IM) or 
doxycycline (100 mg orally administered every 12 hours for 14 days) 
 » Genital herpes: acyclovir (200 mg orally administered 5 times a day 
for 6-7 days) or valaciclovir (1 g orally administered every 12 hours 
for 7-10 days)
 » Soft chancre: azithromycin (1 g orally single dose) or ceftriaxone 
(250 mg IM single dose) or erythromycin (500 mg orally administered 
every 8 hours for 7 days)
 » Lymphogranuloma venereum or granuloma inguinale: azithromycin 
(1 g orally administered once a week for 3 weeks) or doxycycline 
(100 mg orally administered 2 times a day for 21 days)
 » Anogenital warts (1): podophyllin or trichloroacetic acid
 » HIV, hepatitis B and C pharmacological management was not taken 
into account. 
4. Inadequate management: All patients who did not receive 
pharmacological management and those who received another type 
of antimicrobial therapy not recommended by the clinical practice 
guidelines (1,10).
5. Recurrence: Patients with two or more sexually transmitted infection 
episodes through the follow-up period were considered recurrent. 
6. Dispensing of hormonal contraceptives (oral, injectable, or depot) and/
or condoms.
Data analysis
The data were analyzed with the SPSS Statistics, version 26.0 program 
for Windows (IBM, USA). We made a descriptive analysis with frequencies 
and proportions for the qualitative variables and measures of central tendency 
and dispersion for the quantitative variables. The quantitative variables were 
compared using the Student’s t-test or variance analysis and the categorical 
variables using the c2 test. The binary logistic regression models used the 
presence of two or more sexually transmitted infections episodes (recurrence) 
as a dependent variable and those variables significantly associated with 
recurrence in the bivariate analyses as covariates. We adopted p<0.05 as the 
statistical significance level.
Bioethical considerations
The protocol was approved by the Bioethics Committee of the Universidad 
Tecnológica de Pereira under the category of risk-free research (approval 
code: 01-071019). We adhered to the ethical principles established by the 
Declaration of Helsinki and used no personal patient data.
Results
We identified 3,158 patients with a sexually transmitted infections diagnosis 
distributed in 64 different cities or municipalities of whom 63.1% (n=1994) 
were men. The mean age was 41.8 ± 14.5 years (range:14.0–96.8 years) 
distributed in the following age groups: <30 years (n=760; 24.1%), 30-49 years 
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(n=1566; 49.6%), 50-64 years (n=568; 18.0%), and ≥65 years (n=264; 8.4%); 
90.4% (n=2,856) of the patients resided in capital cities.
During the selection period and the follow-up, we found 4,030 sexually 
transmitted infections episodes, predominantly urethral syndrome (n=1108; 
27.5%) distributed as follows: urethritis (n=912; 22.6%), gonorrhea (n=136; 
3.4%), chlamydia (n=32; 0.8%), and trichomoniasis (n=28; 0.7%) followed by 
ulcerative syndrome (n=1,105; 27.4%): syphilis (n=555; 13.8%), genital herpes 
(n=540; 13.4%), and chancre (n=10; 0.3%), as well as genital warts (n=939; 
23.3%), HIV (n=808; 20.0%), and hepatitis B or C (n=70; 1.7%); 83.3% 
(n=2630/3158) of the patients had a single sexually transmitted infections 
episode while 16.7% (n=528) had two or more. At some point during follow-
up, 20.6% (n=649) of the patients were dispensed condoms and 21.0% 
(n=245/1164) of the women, hormonal contraceptives, mostly oral ones 
(n=210/1164; 18.0%).
Sexually transmitted infections pharmacological management
A 13.6% (428/3152) of the urethral syndrome, ulcerative syndrome, and 
genital warts episodes were adequately managed. Genital warts were the 
most frequently treated in compliance with the clinical practice guidelines 
(n=256/939; 27.3%) followed by genital herpes (n=85/540; 15.7%), syphilis 
(n=71/555; 12.8%), gonorrhea (n=14/136; 10.3%), and soft chancre (n=2/10; 
20.0%). No episode of urethritis, chlamydia, or trichomoniasis was managed 
with the recommended antibiotic, dose, and treatment duration. Tables 1, 
2, and 3 show the main drugs used for the treatment of urethral syndrome, 
ulcerative syndrome, and genital warts.
Comorbidities
A total of 68.1% (n=2,151) of patients had some chronic pathology. 
Cardiovascular diseases were the most frequent (n=1,382; 43.8%) followed by 
endocrine (n=845; 26.8%) and digestive disorders (n=541; 17.1%).
Table 1. Pharmacological management of episodes of ulcerative 
syndrome in 3,158 patients with sexually transmitted infections, Colombia 
Syphilis (N=555) n %
Medications included in the management guide 361 65.0
Benzathine penicillin G 337 60.7
Doxycycline 24 4.3
Other antimicrobial management guide 92 16.6
No antimicrobial handling 102 18.4
Genital herpes (N=540) n %
Medications included in the management guide 443 82.0
Acyclovir 414 76.7
Valaciclovir 29 5.4
Other antimicrobial management guide 37 6.9
No antimicrobial handling 60 11.1
Soft chancre (N=10) n %




Other antimicrobial management guide 4 40.0
No antimicrobial handling 0 0.0
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Multivariate analysis
The binary logistic regression analysis showed that being a man under 
30 years of age, being treated in municipalities other than capital cities, 
and having received inadequate treatment for the first sexually transmitted 
infections episode, were associated with a higher probability of another 
episode during the follow-up period. No variable was protective against this 
risk (table 4).
Table 3. Pharmacological management guide of episodes of genital warts 
in 3,158 patients with sexually transmitted infections, Colombia
Table 2. Pharmacological management guide of episodes of urethral 
syndrome in 3,158 patients with sexually transmitted infections, Colombia
Urethritis (N=912) n %
Medications included in the management guide 47 5.2
Ceftriaxone + doxycycline 44 4.8
Ceftriaxone + azithromycin 3 0.3








No antimicrobial handling 99 10.9
Gonorrhea (N=136) n %
Medications included in the management guide 72 52.9
Doxycycline 41 30.1
Ceftriaxone 31 22.8
Other antimicrobial management guide 51 37.5
Ciprofloxacin 16 11.8
Others 35 25.7
No antimicrobial handling 13 9.6
Chlamydia (N=32) n %
Medications included in the management guide 18 56.2
Doxycycline 17 53.1
Azithromycin 1 3.1
Other antimicrobial management guide 6 18.8
Ceftriaxone + ciprofloxacin 2 6.3
Others 4 12.5
No antimicrobial handling 8 25.0
Trichomoniasis (N=28) n %
Medications included in the management guide 20 71.4
Metronidazole 16 57.1
Tinidazole 4 14.3
Other antimicrobial management guide 7 25.0
Fluconazole 3 10.7
Others 4 14.3
No antimicrobial handling 1 3.6
Genital warts (N=939) n %
Medications included in the management guide 314 33.4
Podophyllin 314 33.4
Trichloroacetic acid 0 0.0
Other antimicrobial management guide 429 45.7




No antimicrobial handling 196 20.9
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Discussion
The main sexually transmitted diseases frequencies, their pharmacological 
treatment in compliance with the country’s clinical practice guidelines, and the 
factors associated with having two or more episodes were identified in a cohort 
of patients from both sexes aged 14 and older in a Colombian population.
Similar to our report, in a study in Spain, 27.1% of the patients had urethral 
syndrome (11), and the most frequently found sexually transmitted infection 
was genital warts in agreement with the rate reported by Jacob, et al. in 
Germany (51.2%) (12) but differing from that found in Belgium, where the most 
common sexually transmitted infection was chlamydial infection (43.1%) (13). 
According to WHO reports (4,6) and to a prevalence study from Colombia (7), 
infections caused by Chlamydia trachomatis are the most common infections 
in both men and women. However, in our study, chlamydial infections were 
found in less than 1% of cases due perhaps to the fact that patients were 
classified according to the ICD-10 codes and many of the sexually transmitted 
infections classified as unspecified urethritis were likely chlamydial infections.
Only 13.6% of the urethral syndrome, ulcerative syndrome, and genital 
warts cases treatment adhered to the clinical practice guidelines on antibiotic 
choice, dose, and duration. Inadequate treatment, including the use of 
incorrect antibiotics or sub-therapeutic doses, can lead to multiple treatments 
for the same infection generating an excessive burden on the health system, 
promoting the development of resistance to antibiotics, and reducing the 
effectiveness of current treatments (9). 
The information on this worrisome problem is limited. However, in England, 
Wetten, et al. found that between 2000 and 2011, the proportion of patients 
treated for chlamydial infections increased from 59.5 to 78.4% and that more 
than 90% of them were prescribed the recommended antibiotics; in turn, 
32.7-53.6% of patients diagnosed with gonorrhea received antibiotic treatment 
but, although ciprofloxacin was discontinued as the recommended therapy in 
2005, the authors found that it was prescribed in 42% of the cases in 2007 
and in 20% in 2011 (14). In New Zealand, 65% of patients with gonorrhea 
episodes were managed in compliance with the country guidelines and the 
adherence was greater in patients treated at sexual health clinics (89%) than 
at general medicine clinics (52%) (15). From 2011 to 2014, 50-52% of patients 
with gonorrhea in England were managed according to the guidelines (16). In 
contrast, in the Netherlands, 93.3% of patients with gonorrhea were treated 
with ceftriaxone in compliance with the practice guidelines (17) while in Estonia, 
48.6% of treatments for gonorrhea did not comply with the clinical practice 
guidelines and 3.8% were noncompliant for chlamydia (9).
Table 4. Multivariate analysis of the variables associated with the recurrence of sexually 
transmitted infections 




Age <30 years <0,001 1.729 1.403 2.132
Man 0.007 1.327 1.080 1.631
Treatment in municipalities 0.018 1.439 1.064 1.947
Endocrine diseases 0.077 0.811 0.643 1.023
Having received inadequate treatment in the first episode <0,001 1.913 1.528 2.395
Condom dispensing 0.187 1.167 0.928 1.467
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Recurrence is among the problems related to inadequate sexually 
transmitted infections pharmacological management (3,9). In Belgium, 
reinfections occurred in 15.4% of patients (13); in Brazil in 13.6% (18); in 
Canada in 6.4% (19), and in our study in 17.6% and we documented a 91% 
increase in the risk of recurrence when the recommended medication was not 
administered or when no antimicrobial treatment was indicated. In the United 
States, Amiri, et al. determined that the factors associated with not receiving 
treatment were being a woman (OR=1.25; 95%CI 1.05-1.50) and residing in a 
small town (OR=1.49; 95%CI 1.20-1.86) (20).
In general, sexually transmitted infections are found more frequently in 
men as reported in Belgium (57.3%) (13), but contrary to other studies where 
they predominated in women (21-23). According to several studies, being a 
man is a risk factor for sexually transmitted infections recurrences as informed 
in Brazil (OR=4.28; 95%CI 1.31-14.0) (18), England (OR=9.9; 95%CI 1.32-
73.78) (24), Spain (HR=1.9; 95%CI 1.3-2.8) (25), and in our study (OR=1.32; 
95%CI 1.08-1.63). In addition, those under 25 are considered a high-risk 
population for sexually transmitted infections (8,20) given that according to 
incidence estimates in the US, about 50% of infections occur in women and 
men aged 15-24 years (22). In Spain, López, et al. found that being less than 
20 years (HR=4.1; 95%CI 2.1-8.0) was a risk factor for chlamydial reinfections 
(25), which agrees with our findings that those under 30 years had a 72% 
risk of having a new sexually transmitted infection episode. Older people are 
more aware of the importance of reproductive health care and of prevention, 
detection, and treatment of these infections (20), so they tend to have stable 
relationships and use condoms more frequently (8).
The use of condoms is one of the main strategies to reduce sexually 
transmitted infection transmission, but a reduction in their use has been 
documented among the younger population (8). We found that one-fifth of the 
patients in our study were dispensed condoms in contrast with the case of 
Brazil, where 76.2% of people reported their use, although only 9.1% used 
them regularly (18). In Almeida, et al.’s (18) and our study, condom use was 
not a protective factor against recurrence, maybe because of its inappropriate 
and/or inconsistent use (8).
Our results should be cautiously interpreted since we did not have access 
to the medical records to confirm sexually transmitted infections etiological 
or clinical diagnoses. Additionally, we had no data on the education level, 
the number of sexual partners, the use of illicit drugs, or on antimicrobials, 
contraceptives, or condoms prescribed outside the health system or not 
delivered by the dispensing company, nor on the antiviral management 
received by HIV and hepatitis patients. Finally, it was not possible to establish 
whether the recurrence was due to the lack of treatment of the sexual partner 
or partners or to a de novo infection.
We concluded that the majority of sexually transmitted infection patients 
in our study were not treated in compliance with the Colombian clinical 
practice guidelines and that those not receiving adequate management had 
a higher risk of recurrence, as well as men, adolescents, and young adults. 
For the comprehensive management of sexually transmitted infection patients, 
prescribing physicians should appropriately select the antibiotic, dose, and 
duration of treatment to avoid recurrence. The prescription should be based 
on the available clinical practice guide. The continuous and autonomous 
updating of medical professionals is very important and health administrators 
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can also play a relevant role in promoting the updating of their prescribers. On 
the other hand, more studies on antibiotic sensitivity and resistance patterns 
are required as they are essential for proposing updates in the country’s 
clinical practice guidelines.
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